Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

University of Manitoba

$90,584.00

Developing Novel Integrated Point-of-Care Systems for Chronic Kidney Disease Biomarkers Measurements

EF 2015-16

Résumé
Chronic kidney disease (CKD) is a growing health problem that affects roughly 1.2 million Canadians. Untreated, CKD can lead to kidney failure, a condition that requires treatment with dialysis. Once on dialysis, patients experience poor health and a low quality of life. In addition, dialysis is a very expensive treatment for the Canadian Health System to provide, costing roughly $55,000-$80,000 per patient per year. Kidney failure and dialysis can be prevented if CKD is recognized early. For this reason, the National Kidney Foundation has declared early identification and treatment of CKD to be a priority. Unfortunately, our current ways of finding patients who are at risk of kidney failure are not perfect. Newer tests (biomarkers) have been created that could make finding patients at high risk of kidney failure better, but right now using these tests in clinics is difficult and expensive. Microfluidic Lab-on-Chip (LOC) based systems could make using these new tests easier and less expensive. In this project, we will develop convenient and easy-to-use microfluidic LOC systems for doing 5 of these new tests (hsCRP, NT-proBNP, FGF-23, IL-6, microRNA). Once developed we will then test how well these systems improve the care of patients with kidney disease in the real world.
Programme
Collaborative Health Research Projects
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
462376-2014
Name nom
Lin, Francis
Department département
Physics and Astronomy
Organization id
19
Institution établissement
University of Manitoba
Province en
Manitoba
Province fr
Manitoba
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2014
Award amount
90584
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2
Nb partie
3
Application title
Developing Novel Integrated Point-of-Care Systems for Chronic Kidney Disease Biomarkers Measurements
Keyword
NSERC
Application summary
Chronic kidney disease (CKD) is a growing health problem that affects roughly 1.2 million Canadians. Untreated, CKD can lead to kidney failure, a condition that requires treatment with dialysis. Once on dialysis, patients experience poor health and a low quality of life. In addition, dialysis is a very expensive treatment for the Canadian Health System to provide, costing roughly $55,000-$80,000 per patient per year. Kidney failure and dialysis can be prevented if CKD is recognized early. For this reason, the National Kidney Foundation has declared early identification and treatment of CKD to be a priority. Unfortunately, our current ways of finding patients who are at risk of kidney failure are not perfect. Newer tests (biomarkers) have been created that could make finding patients at high risk of kidney failure better, but right now using these tests in clinics is difficult and expensive. Microfluidic Lab-on-Chip (LOC) based systems could make using these new tests easier and less expensive. In this project, we will develop convenient and easy-to-use microfluidic LOC systems for doing 5 of these new tests (hsCRP, NT-proBNP, FGF-23, IL-6, microRNA). Once developed we will then test how well these systems improve the care of patients with kidney disease in the real world.